{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bicalutamide&page=2", "query": { "intervention": "bicalutamide", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bicalutamide&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T23:53:14.643Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01288911", "title": "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "enzalutamide", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 375, "start_date": "2011-03-22", "completion_date": "2017-11-08", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 36, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 33 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Highland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01288911" }, { "nct_id": "NCT06501911", "title": "A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Recurrent High-grade Glioma" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Intensity-modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2025-04-08", "completion_date": "2025-07-17", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06501911" }, { "nct_id": "NCT00002855", "title": "Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Estramustine Phosphate Sodium", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Nilutamide", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 306, "start_date": "1996-08", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002855" }, { "nct_id": "NCT03141671", "title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "GnRH", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Salvage radiation", "type": "RADIATION" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "MALE", "summary": "18 Years to 95 Years · Male only" }, "enrollment_count": 345, "start_date": "2017-11-24", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 8, "location_summary": "San Diego, California • San Francisco, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141671" }, { "nct_id": "NCT01642732", "title": "Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Everolimus, lupron, bicalutamide, and radiation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1, "start_date": "2012-10", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Ann Arbor, Michigan", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01642732" }, { "nct_id": "NCT00850941", "title": "Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 146, "start_date": "2009-01-26", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2019-05-15", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 3, "location_summary": "Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00850941" }, { "nct_id": "NCT00075192", "title": "CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "CP-675,206 and leuprolide acetate and bicalutamide", "type": "DRUG" }, { "name": "leuprolide acetate and bicalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2004-03", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 11, "location_summary": "La Masa, California • Washington D.C., District of Columbia • Gallatin, Tennessee + 5 more", "locations": [ { "city": "La Masa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gallatin", "state": "Tennessee" }, { "city": "Hermitage", "state": "Tennessee" }, { "city": "Lebanon", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075192" }, { "nct_id": "NCT00482807", "title": "Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "bicalutamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "goserelin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "19 Years to 120 Years · Male only" }, "enrollment_count": 9, "start_date": "2004-08-31", "completion_date": "2010-03-09", "has_results": false, "last_update_posted_date": "2023-11-24", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482807" }, { "nct_id": "NCT00094328", "title": "Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Puberty, Precocious" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "13 Years", "sex": "MALE", "summary": "2 Years to 13 Years · Male only" }, "enrollment_count": 14, "start_date": "2004-11-22", "completion_date": "2017-12-06", "has_results": true, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094328" }, { "nct_id": "NCT00470834", "title": "Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neoplasms, Prostate" ], "interventions": [ { "name": "dutasteride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "40 Years to 90 Years · Male only" }, "enrollment_count": 127, "start_date": "2007-05", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-09-15T23:53:14.643Z", "location_count": 47, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470834" } ] }